Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity Featured Article: Ricardo V. Cohen, M.D., Jose C. Pinheiro, M.D., Carlos A. Schiavon, M.D., João E. Salles, M.D., Bernardo L. Wajchenberg, M.D., David E. Cummings, M.D. Diabetes Care Volume 35: 1420-1 428 July, 2012
9
Embed
Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity
Featured Article :. Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity. Ricardo V. Cohen, M.D., Jose C. Pinheiro, M.D., Carlos A. Schiavon, M.D., João E. Salles, M.D., Bernardo L. Wajchenberg, M.D., David E. Cummings, M.D. Diabetes Care - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity
Featured Article:
Ricardo V. Cohen, M.D., Jose C. Pinheiro, M.D., Carlos A. Schiavon, M.D., João E. Salles, M.D., Bernardo L. Wajchenberg, M.D., David E. Cummings,
• Roux-en-Y gastric bypass (RYGB) ameliorates type 2 diabetes in severely obese patients through mechanisms beyond just weight loss, and it may benefit less obese diabetic patients
• Study determined the long-term impact of RYGB on patients with diabetes and only class I obesity (BMI 30–35 kg/m2 )
Study Design & Methods
• Sixty-six consecutively selected diabetic patients with BMI 30–35 kg/m2 underwent RYGB in a tertiary-care hospital and were prospectively studied for up to 6 years (median 5 years [range 1–6]), with 100% follow-up
• Main outcome measures were safety and the percentage of patients experiencing diabetes remission (HbA1c < 6.5% without diabetes medication)
Cohen R et al. Diabetes Care 2012;35:1420-1428
Cohen R et al. Diabetes Care 2012;35:1420-1428
Cohen R et al. Diabetes Care 2012;35:1420-1428
Cohen R et al. Diabetes Care 2012;35:1420-1428
Cohen R et al. Diabetes Care 2012;35:1420-1428
Cohen R et al. Diabetes Care 2012;35:1420-1428
Conclusions
• Largest, longest-term study to date examining RYGB for diabetic patients without severe obesity
• RYGB safely and effectively ameliorated diabetes and associated comorbidities, reducing cardiovascular risk, in patients with a BMI of only 30–35 kg/m2